Nanomaterials targeting cancer-associated fibroblasts to overcome stromal barriers in cancer immunotherapy
6 affiliations
- 1Non-Coding RNA and Drug Discovery Key Laboratory of Sichuan Province, School of Basic Medical Sciences, Chengdu Medical College, Chengdu, 610550, Sichuan, China
- 2School of Basic Medical Sciences, Chengdu Medical College, Chengdu, 610550, China
- 3The Second Affiliated Hospital of Chengdu Medical College, Nuclear Industry 416 Hospital, Chengdu, 610000, Sichuan, China
- 4Non-Coding RNA and Drug Discovery Key Laboratory of Sichuan Province, School of Basic Medical Sciences, Chengdu Medical College, Chengdu, 610550, Sichuan, China. [email protected]
- 5School of Basic Medical Sciences, Chengdu Medical College, Chengdu, 610550, China. [email protected]
- 6The Second Affiliated Hospital of Chengdu Medical College, Nuclear Industry 416 Hospital, Chengdu, 610000, Sichuan, China. [email protected]
Abstract
Cancer-associated fibroblasts (CAFs) play a pivotal role in the tumor microenvironment (TME), influencing tumor progression, immune evasion, metastasis, and resistance to therapy. In parallel, emerging evidence underscores the therapeutic potential of targeting CAFs in cancer treatment. While CAFs exhibit significant heterogeneity, with different subtypes contributing to various aspects of tumor biology, including ECM remodeling, immune modulation, and cancer cell proliferation. This complexity presents a challenge in targeting CAFs for effective cancer therapy. Recent advancements in nanotechnology have offered novel strategies for precisely targeting CAFs, thereby modulating the TME to enhance the efficacy of cancer immunotherapy. This review provides a comprehensive overview of CAF biology, the mechanisms through which CAFs contribute to immune suppression and therapy resistance, and the emerging role of CAF-targeted nanomedicines in overcoming these barriers. Key strategies discussed include CAF reprogramming, ECM barrier disruption, and the targeting of immune checkpoints, all aimed at reshaping the TME into a more immune-permissive environment. However, despite promising preclinical results, several challenges remain, such as optimizing nanoparticle delivery, overcoming CAF-related drug resistance, and addressing the complex immunosuppressive networks within the TME. Future research should focus on the development of more targeted and personalized nanomedicine approaches, improving CAF-specific drug delivery systems, and better understanding the dynamic interactions between CAFs and the immune system. Our review highlights the current advances in CAF-targeted nanomedicine and underscores the importance of these strategies in advancing cancer immunotherapy. Ultimately, overcoming the challenges associated with CAF-targeted therapies could significantly improve clinical outcomes and pave the way for more effective, individualized cancer treatments.
Related
- Targeting the Helicobacter pylori–Gastric Cancer Axis with Nanomaterials: From Infection Control to Tumor-Directed Therapy
- Targeting histone methylation with ROS nanoparticles delivering PARPi prodrugs to amplify the stimulation of cGAS-STING for immunotherapy in ovarian cancer
- Screening colorectal tumor-associated fibroblasts using dual-channel THz biosensor
- CRISPR/Cas9-Directed PEPD Targeting Is Associated with Reduced PEPD Activity and an Exploratory p53- and Apoptosis-Related Protein Pattern in MCF7 Breast Cancer Cells
- Application and Research of Laser Manufacturing Technology in Nanomaterials
BibTeX
@article{zhang2026nanomaterials,
title = {{Nanomaterials targeting cancer-associated fibroblasts to overcome stromal barriers in cancer immunotherapy}},
author = {Zhongsong Zhang and Wang Rong and L Chen},
journal = {Journal of Nanobiotechnology},
year = {2026},
month = may,
doi = {10.1186/s12951-026-04567-z},
url = {https://doi.org/10.1186/s12951-026-04567-z},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Nanomaterials targeting cancer-associated fibroblasts to overcome stromal barriers in cancer immunotherapy
AU - Zhongsong Zhang
AU - Wang Rong
AU - L Chen
PY - 2026
DA - 2026/05/22
JO - Journal of Nanobiotechnology
DO - 10.1186/s12951-026-04567-z
UR - https://doi.org/10.1186/s12951-026-04567-z
AB - Cancer-associated fibroblasts (CAFs) play a pivotal role in the tumor microenvironment (TME), influencing tumor progression, immune evasion, metastasis, and resistance to therapy. In parallel, emerging evidence underscores the therapeutic potential of targeting CAFs in cancer treatment. While CAFs exhibit significant heterogeneity, with different subtypes contributing to various aspects of tumor biology, including ECM remodeling, immune modulation, and cancer cell proliferation. This complexity presents a challenge in targeting CAFs for effective cancer therapy. Recent advancements in nanotechnology have offered novel strategies for precisely targeting CAFs, thereby modulating the TME to enhance the efficacy of cancer immunotherapy. This review provides a comprehensive overview of CAF biology, the mechanisms through which CAFs contribute to immune suppression and therapy resistance, and the emerging role of CAF-targeted nanomedicines in overcoming these barriers. Key strategies discussed include CAF reprogramming, ECM barrier disruption, and the targeting of immune checkpoints, all aimed at reshaping the TME into a more immune-permissive environment. However, despite promising preclinical results, several challenges remain, such as optimizing nanoparticle delivery, overcoming CAF-related drug resistance, and addressing the complex immunosuppressive networks within the TME. Future research should focus on the development of more targeted and personalized nanomedicine approaches, improving CAF-specific drug delivery systems, and better understanding the dynamic interactions between CAFs and the immune system. Our review highlights the current advances in CAF-targeted nanomedicine and underscores the importance of these strategies in advancing cancer immunotherapy. Ultimately, overcoming the challenges associated with CAF-targeted therapies could significantly improve clinical outcomes and pave the way for more effective, individualized cancer treatments.
SN - 1477-3155
ER -